MELA Sciences to Report Third Quarter Financial Results on Thursday, November 12
Conference Call to Follow at 4:30 p.m. EDT
Get Alerts MELA Hot Sheet
Join SI Premium – FREE
HORSHAM, Pa., Oct. 29, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (NASDAQ: MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release third quarter financial results on Thursday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
Conference Call Details: | |
Date: | Thursday, November 12 |
Time: | 4:30pm Eastern Time |
Toll Free: | 888-430-8691 |
International: | 719-325-2376 |
Passcode: | 714691 |
Webcast: | www.melasciences.com |
Replays, available through November 26, 2015 | |
Toll Free: | 877-870-5176 |
International: | 858-384-5517 |
Replay PIN: | 714691 |
About MELA Sciences, Inc. (www.melasciences.com)
MELA Sciences is a medical technology company focused in the dermatology market. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the MelaFind System used to assist in the identification and management of melanoma skin cancer.
CONTACT: Investor Contacts: Robert W. Cook MELA Sciences, Inc. 914 373 6936 [email protected] Andrew McDonald LifeSci Advisors, LLC 646-597-6987 [email protected]Source: MELA Sciences
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Achieve Life Sciences (ACHV) Tops Q4 EPS by 5c
- Planet Labs (PL) Reports In-Line Q4 EPS, provides guidance
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!